Clinical Aspects of Variant Creutzfeldt‐Jakob Disease

Allroggen, 2000, New variant Creutzfeldt‐Jakob disease: three case reports from Leicester, JNNP, 68, 375 Alperovitch, 2002, Predicting the size of the vCJD epidemic in France, CR Biologies, 325, 33, 10.1016/S1631-0691(02)01410-5 Alperovitch, 1999, Codon 129 prion protein genotype and sporadic Creutzfeldt‐Jakob disease, Lancet, 353, 1673, 10.1016/S0140-6736(99)01342-2 Al‐Shahi, 2001, Amount of research interest in rare and common neurological conditions: bibliometric study, BMJ, 323, 1461, 10.1136/bmj.323.7327.1461 Andrews, 2000, Incidence of variant Creutzfeldt‐Jakob disease in the UK, Lancet, 356, 481, 10.1016/S0140-6736(00)02559-9 Andrews, 2003, Deaths from variant Creutzfeldt‐Jakob disease in the UK, Lancet, 361, 751, 10.1016/S0140-6736(03)12632-3 Boelle, 2003, Modelling the epidemic of variant Creutzfeldt‐Jakob disease in the UK based on age characteristics: updated, detailed analysis, Stat Methods Med Res, 12, 221, 10.1191/0962280203sm329ra Brown, 1985, Epidemiologic implications of Creutzfeldt‐Jakob disease in a 19 year old girl, Eur J Epidemiol, 1, 42, 10.1007/BF00162311 Bruce, 1997, Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent, Nature, 389, 498, 10.1038/39057 Bruce, 2001, Detection of variant Creutzfeldt‐Jakob disease infectivity in extraneural tissues, Lancet, 358, 208, 10.1016/S0140-6736(01)05411-3 Bryant, 2001 Chadeau‐Hyman, 2005, Risk of variant Creutzfeldt‐Jakob Disease in France, Int J Epidemiol, 23, 1 Clarke, 2005, Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility, J R Soc Interface, 2, 19, 10.1098/rsif.2004.0017 Collie, 2001, MRI of Creutzfeldt‐Jakob disease: imaging features and recommended MRI protocol, Clinical Radiology, 56, 726, 10.1053/crad.2001.0771 Collie, 2003, Diagnosing variant Creutzfeldt‐Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases, Am J Neuroradiol, 24, 1560 Collinge, 1996, Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD, Nature, 383, 685, 10.1038/383685a0 Collins, 2002, Quinacrine does not prolong survival in a murine Creutzfeldt‐Jakob disease model, Ann Neurol, 52, 503, 10.1002/ana.10336 Cooper, 2002, UK dietary exposure to BSE in heat meat: by birth cohort and gender, J Cancer Epidemiol Prevent, 7, 71, 10.1080/147666502321082737 Cousens, 1997, Predicting the CJD epidemic in humans, Nature, 385, 197, 10.1038/385197a0 Cousens, 1999, Geographical distribution of variant CJD in the UK (excluding Northern Ireland), Lancet, 353, 18, 10.1016/S0140-6736(98)08062-3 1999 Doh‐ura, 2000, Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie‐associated prion protein accumulation, J Virol, 74, 4894, 10.1128/JVI.74.10.4894-4897.2000 Doh‐ura, 2004, Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models, J Virol, 78, 4999, 10.1128/JVI.78.10.4999-5006.2004 Ferguson, 1999, Predicting the size of the epidemic of the new variant of Creutzfeldt‐Jakob disease, Brit Food J, 101, 86, 10.1108/00070709910261891 Ghani, 1998, Epidemiological determinants of the pattern and magnitude of the vCJD epidemic in Great Britain, Proc R Soc Lond B, 265, 2443, 10.1098/rspb.1998.0596 Ghani, 2000, Predicted vCJD mortality in Great Britain, Nature, 406, 583, 10.1038/35020688 Green, 2002, Use of 14–3‐3 in the diagnosis of Creutzfeldt‐Jakob disease, Biochem Soc Trans, 30, 382, 10.1042/bst0300382 Green, 2001, Use of 14–3‐3 and other brain‐specific proteins in CSF in the diagnosis of variant Creutzfeldt‐Jakob disease, JNNP, 2001, 744 Green, 2002, 14–3‐3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt‐Jakob disease measured using a highly sensitive 14–3–3 protein capture assay, Neurosci Lett, 324, 57, 10.1016/S0304-3940(02)00172-6 Gregory, 1990 Hahn, 1994, Unusual MRI findings after status epilepticus due to cat‐scratch disease, Pediatr Neurol, 10, 255, 10.1016/0887-8994(94)90035-3 Haik, 2002, Sporadic CJD mimicking variant CJD with bilateral high signal in the pulvinar, Neurology, 58, 148, 10.1212/WNL.58.1.148-a Haik, 2004, Compassionate use of quinacrine in Creutzfeldt‐Jakob disease fails to show significant effects, Neurology, 63, 2413, 10.1212/01.WNL.0000148596.15681.4D Harding, 1995, Progressive neuronal degeneration of childhood with liver disease (Alper's disease) presenting in young adults, JNNP, 58, 320 Hill, 1997, The same prion strain causes vCJD and BSE, Nature, 389, 448, 10.1038/38925 Hill, 1997, Diagnosis of new variant Creutzfeldt‐Jakob disease by tonsil biopsy, Lancet, 349, 99, 10.1016/S0140-6736(97)24002-X Hill, 1999, Investigation of variant Creutzfeldt‐Jakob disease and other human prion diseases with tonsil biopsy samples, Lancet, 353, 183, 10.1016/S0140-6736(98)12075-5 Hillier, 2001, Creutzfeldt‐Jakob disease in a young person with valine homozygosity at codon129: sporadic or variant?, JNNP, 70, 134 Hilton, 1998, Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt‐Jakob disease, Lancet, 352, 703, 10.1016/S0140-6736(98)24035-9 Houston, 2000, Transmission of BSE by blood transfusion in sheep, Lancet, 356, 999, 10.1016/S0140-6736(00)02719-7 Hsich, 1996, The 14–3‐3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies, N Engl J Med, 335, 924, 10.1056/NEJM199609263351303 Huillard d'Aignaux, 1999, Incubation period of Creutzfeldt‐Jakob disease in human growth hormone recipients in France, Neurology, 53, 1197, 10.1212/WNL.53.6.1197 Huillard d'Aignaux, 2002, The incubation period of kuru, Epidemiology, 13, 402, 10.1097/00001648-200207000-00007 Hunter, 2002, Transmission of prion diseases by blood transfusion, J Gen Virol, 83, 2897, 10.1099/0022-1317-83-11-2897 Kapur, 2003, The neuropsychological profile associated with variant Creutzfeldt‐Jakob disease, Brain, 126, 2693, 10.1093/brain/awg279 Kay, 2001, Variant Creutzfeldt‐Jakob disease in Hong Kong, HKMJ, 7, 296 Korth, 2001, Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease, Proc Natl Acad Sci U S A, 98, 9836, 10.1073/pnas.161274798 Kulczycki, 1991, Creutzfeldt‐Jakob disease in young people, Eur J Epidemiol, 7, 501, 10.1007/BF00143129 La Bella, 2002, Variant Creutzfeldt‐Jakob disease in an Italian woman, Lancet, 360, 997, 10.1016/S0140-6736(02)11085-3 Lasmezas, 1996, BSE transmission to macaques, Nature, 381, 743, 10.1038/381743a0 Lasmezas, 2005, Risk of oral infection of BSE in primates, Lancet, 365, 781, 10.1016/S0140-6736(05)17985-9 Lepine, 2004, The epidemiology of pain in depression, Human Pyschopharmacology, 19, 5 Lewis, 2005, Australian sporadic CJD analysis supports endogenous determinants of molecular‐clinical profiles, Neurology, 65, 113, 10.1212/01.wnl.0000167188.65787.a0 Llewelyn, 2004, Possible transmission of variant Creutzfeldt‐Jakob disease by blood transfusion, Lancet, 363, 417, 10.1016/S0140-6736(04)15486-X Macleod, 2000, Sensory features of variant Creutzfeldt‐Jakob disease, JNNP, 69, 413 Martindale, 2003, Sporadic Creutzfeldt‐Jakob disease mimicking variant Creutzfeldt‐Jakob disease, Ann Neurol, 60, 767, 10.1001/archneur.60.5.767 Monreal, 1981, Creutzfeldt‐Jakob disease in an adolescent, J Neurosci, 52, 341 2005 1989 Peden, 2004, Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient, Lancet, 364, 527, 10.1016/S0140-6736(04)16811-6 Petzold, 2004, False‐positive pulvinar sign on MRI in sporadic Creutzfeldt‐Jakob disease, Neurology, 62, 1234, 10.1212/01.WNL.0000123265.91365.AF Pocchiari, 2004, Predictors of survival in sporadic Creutzfeldt‐Jakob disease and other human transmissible spongiform encephalopathies, Brain, 127, 2348, 10.1093/brain/awh249 Scott, 1999, Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans, Proc Natl Acad Sci U S A, 96, 15137, 10.1073/pnas.96.26.15137 Sellar, 1997, MR imaging of new variant Creutzfeldt‐Jakob disease: the pulvinar sign, Neuroradiology, 39, S53 Smith, 1992, The epidemiology and treatment of depression when it co‐exists with somatoform disorders, somatization or pain, Gen Hosp Psychiatry, 14, 265, 10.1016/0163-8343(92)90097-T Spencer, 2002, First hundred cases of variant Creutzfeldt‐Jakob disease: retrospective case note review of early psychiatric and neurological features, BMJ, 324, 1479, 10.1136/bmj.324.7352.1479 Todd, 2005, Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt‐Jakob disease, J Infection, 50, 394, 10.1016/j.jinf.2004.07.015 Valleron, 2001, Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom, Science, 294, 1726, 10.1126/science.1066838 Ward, 2006, Risk factors for variant Creutzfeldt‐Jakob disease: a case‐control study, Ann Neurol, 59, 111, 10.1002/ana.20708 Wiersman, 2002, Probable vCJD in a US resident, MMWR, 51, 927 Will, 1996, A new variant of Creutzfeldt‐Jakob disease in the UK, Lancet, 347, 921, 10.1016/S0140-6736(96)91412-9 Will, 1999, Infectious and sporadic prion diseases, 465 Will, 1999, Psychiatric features of new variant Creutzfeldt‐Jakob disease, Psychiatric Bulletin, 23, 264, 10.1192/pb.23.5.264 Will, 2000, Diagnosis of new variant Creutzfeldt‐Jakob disease, Ann Neurol, 47, 575, 10.1002/1531-8249(200005)47:5<575::AID-ANA4>3.0.CO;2-W 2002 Yoshimura, 1992, A case of benign intracranial hypertension with bilateral reversible thalamic lesions on magnetic resonance imaging, Clin Neurol, 32, 327 Zeidler, 1997, New variant Creutzfeldt‐Jakob disease: psychiatric features, Lancet, 350, 908, 10.1016/S0140-6736(97)03148-6 Zeidler, 1997, New variant Creutzfeldt‐Jakob disease: neurological features and diagnostic tests, Lancet, 350, 903, 10.1016/S0140-6736(97)07472-2 Zeidler, 2000, The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt‐Jakob disease, Lancet, 355, 1412, 10.1016/S0140-6736(00)02140-1 Zerr, 2000, Analysis of EEG and CSF 14–3–3 proteins as aids to the diagnosis of Creutzfeldt‐Jakob disease, Neurology, 55, 811, 10.1212/WNL.55.6.811